Theravance Biopharma, Inc. — Net Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/af9377a7-909b-41cc-a112-a5b52e1da5e0/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $105.9M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-033077 |
| FY 2024 | $-56.4M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-002447 |
| FY 2023 | $-55.2M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-002267 |
| FY 2022 | $872.1M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-002595 |
| FY 2021 | $-199.4M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-002373 |
| FY 2020 | $-278.0M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-002006 |
| FY 2019 | $-236.5M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-001644 |
| FY 2018 | $-215.5M | 2018-01-01 – 2018-12-31 | evidence 0001558370-19-001346 |
| FY 2017 | $-285.4M | 2017-01-01 – 2017-12-31 | evidence 0001047469-18-001160 |
| FY 2016 | $-190.7M | 2016-01-01 – 2016-12-31 | evidence 0001047469-17-001086 |
| FY 2015 | $-182.2M | 2015-01-01 – 2015-12-31 | evidence 0001047469-16-011039 |
| FY 2014 | $-237.0M | 2014-01-01 – 2014-12-31 | evidence 0001047469-15-002175 |
| FY 2013 | $-156.3M | 2013-01-01 – 2013-12-31 | evidence 0001047469-15-002175 |
| FY 2012 | $-9.6M | 2012-01-01 – 2012-12-31 | evidence 0001047469-15-002175 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Theravance Biopharma, Inc. — all facts · Revenue · Operating Income